by AI-driven Drug Discovery Aids Approval of Niclosamide for COVID-19 Treatment
The ongoing COVID-19 (coronavirus) outbreak has fueled an unprecedented demand for drugs that are capable of fighting off the novel infection. Hence, AI (Artificial Intelligence) firm Gero is gaining global recognition for specializing in the AI-driven drug discovery and validating promising potentials of anthelmintic drugs for the treatment of COVID-19. As such, niclosamide is found to be potentially effective for the treatment of coronavirus in patients and has been approved in the U.S., Italy, France, and few other countries where there is a high prevalence of active COVID-19 patients.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111858
Due to the approval of niclosamide, companies in the anthelmintic drugs market are increasing their efficacy in AI-driven drug discovery methods to capitalize on revenue generation opportunities. Companies in the anthelmintic drugs market are taking efforts to conduct clinical trials in existing drugs that may be useful in coronavirus treatment.
Sponsored Collaborations Fuel Research in New Drug Candidates for Soil-transmitted Infections
An alarmingly right prevalence of parasitic worm infections in humans has forced companies in the anthelmintic drugs market to increase their R&D capabilities for new drug candidates. For instance, in December 2019, Bayer Animal Health — a global provider of innovative solutions for animal health, revealed that the company is increasing its research efforts to provide promising anthelmintic drug candidates for the EU-sponsored collaboration called Project HELP (Helminth Elimination Platform) meant for human treatment.
Get a glimpse of the in-depth analysis through our Report Brochure
Companies in the anthelmintic drugs market are entering into strategic collaborations in order to find new treatments for ascaris lumbricoides (Roundworm) infection. This explains why the revenue for roundworm target pathogen is estimated to dictate the highest value in the anthelmintic drugs market, resulting in anticipated revenue generation of ~US$ 4 Bn by the end of 2030. The growing awareness about soil-transmitted infections and filarial infections in humans is bolstering innovations in anthelmintic drugs.
Biologically Active Substances of Medicinal Plants Hold Promising Potentials for Drug Discovery
Plant-based products are being highly publicized for the development of anthelmintic drugs that are capable of treating nematodes. Currently, intestinal parasitic nematodes are a serious issue in human as well as animals. As such, animals dominate a higher revenue share as compared to humans in the anthelmintic drugs market, where the market is slated to progress at a CAGR of ~5% during the forecast period. However, anthelmintic drug resistance in humans and animals is a challenge for pharmaceutical companies. Hence, companies are using medicinal plant ingredients for the discovery of new anthelmintic drugs.
Companies in the anthelmintic drugs market are increasing their research efforts to study the biologically active substances of medicinal plants that possess drug-like properties and hold promising potentials for the treatment of intestinal parasitic nematodes in human as well as animals. As such, medicinal plant-derived drugs, such as artemether, tiopropium and galantamine are generating revenue streams for pharmaceutical companies.
Combination Therapy Awaits Confirmed Clinical Trials to Deploy Widespread Adoption in Veterinary Clinics
Various preventive measures are being adopted to control parasites in donkeys. Since vaccines are not readily available and there is a need for the development of better vaccines, veterinary doctors are relying on anthelmintic drugs to protect the health of donkeys. As such, companies in the anthelmintic drugs market are tapping value-grab opportunities by increasing the availability of benzimidazoles macrocyclic lactones and tetrahydropyrimidines to improve the health of donkeys.
In order to effectively manage the issue of drug resistance in donkeys, companies in the anthelmintic drugs market are educating veterinarians to gain better knowledge of local parasite epidemiology and its correlation with anthelmintic drugs. The trend of combination therapy is surging, as veterinarians are using different combination of drugs to improve clinical numbers of donkeys. However, there is a need for confirmed clinical trials to support the validation of combination therapy. Since donkeys ingest third-stage larvae from grazing, there is a need for sound grazing management practices. The practice of FEC (Fecal Egg Count)-directed treatment is another alternative treatment, which is benefitting the health of donkeys.
Analysts’ Viewpoint
With the approval of niclosamide in the U.S. and Italy, AI is predicted to play a crucial role in drug discovery methodologies for COVID-19 treatment. As such, anti-cancer effects of anthelmintics are being recognized by healthcare systems in Korea.
Medicinal plants hold promising potentials for innovations in anthelmintics. However, anthelmintic resistance is a recurring problem that needs to be addressed by pharmaceutical companies. Hence, companies should sponsor research-based communities that conduct aggressive research on the prevention of anthelmintic resistance. They should direct their investments in preserving the drug efficacy and increase research in anthelmintic resistance management and awareness about hygienic grazing methods to improve the health of animals.
Anthelmintic Drugs Market: Overview
The global anthelmintic drugs market for the historical period 2018–2019 and forecast period 2020–2030, increase in incidence of helminth infection across the globe, innovative drug launch for gastrointestinal nematodes, government initiatives, and rise in pet ownership and spending on companion animals are expected to drive the global market during the forecast period
According to the report, the anthelmintic drugs market was valued at ~US$ 2 Bn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030
Increase in Incidence of Helminth Infection Worldwide: Key Drivers
Rise in prevalence of helminth infections caused by roundworm, hookworm, whipworm, and others worms is anticipated to drive the need of anthelmintic drugs for the treatment of the same
Soil transmitted helminth infections are caused by various species of parasitic worms. According to the WHO, as of March 2020, nearly 1.5 billion humans were suffering from soil transmitted helminth infection across the globe. This number accounts for 24% of the global human population. Major species increasing the disease burden are ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale (hookworms).
According to the WHO data, in March 2020, distribution of soil-transmitted helminth infection was higher in sub-Saharan Africa, the Americas, China, and countries in Asia. Globally, 267 million preschool children and 568 million schoolchildren in the above areas are suffering from helminth infections.
Moreover, S. stercoralis are estimated to be affecting around 600 million people globally. Poor hygiene and sanitation are the other factors boosting incidence of soil-transmitted helminth infections across the globe.
Government Initiatives to Boost Market Growth
Initiatives and paradigm shift in focus of governments toward contributing in managing the helminth infections across the globe are anticipated to boost the market for anthelmintic drugs
For instance, the National Deworming Day is a major initiative by the Ministry of Health and Family Welfare, Government of India, to make the country worm-free. According to the WHO, 241 million children in the age group 1 to 14 years are at a higher risk of parasitic intestinal worms in India. Hence, the government is likely to develop guidelines for creating awareness and eradicate helminth infection.
Anthelmintic drugs are the primary controlling measure for eradicating worms in livestock. Annual cost of parasitic diseases is estimated to be US$ 1 Bn in Australia and US$ 7.11 Bn in Brazil. Hence, standard policies for treatment of worm infection in humans and livestock are of prime importance in every country.
Anthelmintic Drug Resistance to Hamper Market
Anthelmintic drugs are the most preferred and efficient treatment for fighting helminthiasis in animals and humans. However, multidrug-resistance is a major concern in livestock, especially in the two new classes such as aminoacetonitrile derivatives and paraherquamide derivatives.
Rise in multidrug-resistance would pressurize producers and animal health professionals to develop alternative methods of treatment. Thus, rise in drug resistance to most commonly prescribed anthelmintic drugs by parasitic helminths is likely to restrain the market during the forecast period. Helminthiasis has been reported to develop resistance to drugs such as Levamisole, morantel, Benzimidazole, Albendazole, Avermectin, and Ivermectinin the past few years.
Resistance to anthelmintic drugs is a major concern in sheep-producing countries in Europe. Multidrug & multispecies resistance is increasing at a rapid pace in South America. This is anticipated to restrain the global anthelmintic drugs market. According to a research, resistance against monepantel and derquantel has already been reported, which has increased the risk factor associated with anthelmintic resistance.
Anthelmintic Drugs Market: Competition Landscape
This report profiles major players in the global anthelmintic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global anthelmintic drugs market is highly fragmented with the presence of a number of international as well as regional players
Leading players operating in the global anthelmintic drugs market include
- Novartis AG
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd
- Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
- Zoetis, Inc.
- GlaxoSmithKline plc
- Bayer AG
- Merck & Co., Inc. (Intervet Inc.)
- Boehringer Ingelheim International GmbH
Key Questions Answered in Anthelmintic Drugs Market Report
- What is the sales/revenue generated by the global anthelmintic drugs market across all the regions during the forecast period?
- What are the key trends in the global anthelmintic drugs market?
- What are the major drivers, restraints, and opportunities in the global market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which segment will have the highest revenue globally in 2030 and which drug class will expand at the fastest CAGR during the forecast period?
Anthelmintic Drugs Market – Segmentation
Drug Class
- Benzimidazoles
- Piperazine
- Others
Route of Administration
- Oral
- Injectable
Application
- Human
- Parenchymal Neurocysticercosis
- Gastrointestinal Infections
- Animal
Target Pathogen
- Ascaris Lumbricoides (Roundworm)
- Trichuris Trichiura (Whipworm)
- Enterobius Vermicularis (Pinworm)
- Ancylostoma Duodenale (Hookworm)
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Veterinary Pharmacies
- Veterinary Hospitals & Clinics
Region
- Europe
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111858/2900
